01 October 2024
01 October 2024
The European Commission approved Johnson and Johnson’s Yuvanci as the first single-pill combination therapy for PAH.
The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage III or IV non-small cell lung cancer.
Modalis may receive a priority review voucher if its CMD gene therapy is approved by the FDA.
Convincing healthcare providers and patients of Neffy’s reliability during allergic reactions will require extensive education and further evidence from post-market surveillance.
Ten years on from their approval, GlobalData reviews their market entry strategies, pricing dynamics over time, and respective HTA evaluations.
The round was led by RA Capital Management, with RTW Investments and Janus Henderson Investors as co-leaders.
The site is an essential part of the company's programme, ADCelerate, for developing and making ADCs.
BPM31510IV is also a lead candidate to treat solid tumours such as glioblastoma multiforme and pancreatic cancer.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
